Literature DB >> 18422080

[Neuroprotection in perinatal hypoxic-ischemic encephalopathy. Effective treatment and future perspectives].

Agustín Legido1, Ignacio Valencia, Christos D Katsetos, María Delivoria-Papadopoulos.   

Abstract

The aim of this paper is to review the results of recent clinical studies of some therapies that have demonstrated a neuroprotective effect in perinatal hypoxic-ischemic encephalopathy (HIE) and to present the future perspectives of other clinical and basic research investigations. THERAPIES WITH DEMONSTRATED CLINICAL EFFICACY: ALLOPURINOL: It blocks the production of free radicals following hypoxia-ischemia. In a recent study, infants with hypoplastic left heart syndrome treated with allopurinol, but not those with other congenital cardiopathies, had significantly less number of complications than controls, including death, seizures, coma or cardiac events. OPIOIDS: In another recent study, newborns with HIE treated with morphine or phentanyl, had less severe brain damage on MRI and a better neurological outcome. HYPOTHERMIA: Both local (head cooling) or systemic (whole body) hypothermia have a neuroprotective effect in selected newborns with HIE. FUTURE PERSPECTIVES: ANTIEPILEPTIC DRUGS: They have multiple mechanisms of action that can block the biochemical cascade of neuronal damage in HIE. OTHER THERAPEUTIC MODALITIES: Among them the following should be emphasized: combined neuroprotective treatments, growth factors, genetic therapies, stem cell transplant, and neuroprotective immunization. In conclusion, a better knowledge of the molecular mechanisms of HIE pathogenesis and better clinical studies of neuroprotective therapies will open new possibilities aplicable to clinical practice. These advances will undoubtedly improve the prognosis of newborns with HIE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18422080

Source DB:  PubMed          Journal:  Medicina (B Aires)        ISSN: 0025-7680            Impact factor:   0.653


  4 in total

1.  Putative agmatinase inhibitor for hypoxic-ischemic new born brain damage.

Authors:  John E Piletz; Stephanie Klenotich; Ken S Lee; Qian Long Zhu; Edward Valente; Michael A Collins; Vyvyca Jones; Soeb Nam Lee; Feng Yangzheng
Journal:  Neurotox Res       Date:  2013-01-19       Impact factor: 3.911

2.  Platelet-Rich Plasma in a Patient with Cerebral Palsy.

Authors:  Jesús Alcaraz; Antonio Oliver; Juana María Sánchez
Journal:  Am J Case Rep       Date:  2015-07-17

Review 3.  Oxidative Stress in Hypoxic-Ischemic Encephalopathy: Molecular Mechanisms and Therapeutic Strategies.

Authors:  Mingyi Zhao; Ping Zhu; Masayuki Fujino; Jian Zhuang; Huiming Guo; IdrisAhmed Sheikh; Lingling Zhao; Xiao-Kang Li
Journal:  Int J Mol Sci       Date:  2016-12-10       Impact factor: 5.923

4.  Using the endocannabinoid system as a neuroprotective strategy in perinatal hypoxic-ischemic brain injury.

Authors:  I Lara-Celador; F Goñi-de-Cerio; Antonia Alvarez; Enrique Hilario
Journal:  Neural Regen Res       Date:  2013-03-15       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.